Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.
Exp Biol Med (Maywood). 2013 May;238(5):442-9. doi: 10.1177/1535370213480696.
Human immunodeficiency virus (HIV) afflicts an estimated 30 million people globally, making it a continuing pandemic. Despite major research efforts, the rate of new infections has remained relatively static over time. This article reviews an emerging strategy for the treatment of HIV, the inhibition of the co-receptors necessary for HIV entry, CCR5 and CXCR4. The aim of this article is to highlight potential therapeutics derived from peptides and proteins that show particular promise in HIV treatment. Molecules that act on CCR5, CXCR4 or on both receptors will be discussed herein.
人类免疫缺陷病毒（HIV）估计在全球范围内影响了 3000 万人，使其成为持续的大流行病。尽管进行了重大的研究努力，但新感染的速度随着时间的推移一直保持相对稳定。本文综述了一种新兴的 HIV 治疗策略，即抑制 HIV 进入所需的辅助受体 CCR5 和 CXCR4。本文的目的是强调从在 HIV 治疗中显示出特殊前景的肽和蛋白质中获得的潜在治疗剂。本文将讨论作用于 CCR5、CXCR4 或这两种受体的分子。
